BioSpace News Archive

NeuX Technologies , a leading provider of advanced medical technology for the health, wellness, fitness and human performance markets, is excited to announce Dr. Tim Brown has joined NeuX as Chief Innovation Officer.

Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca’s exenatide extended-release 2mg once weekly significantly reduced blood sugar—as measured by HbA1c—versus placebo in adolescents aged 10–17 with type 2 diabetes (T2D).

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share,

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that its common shares have been approved for trading on the OTCQB® Market (“OTCQB”) effective Monday June 28, 2021.

Hepion Pharmaceuticals, Inc. today announced that its 2021 Annual Meeting of Stockholders, scheduled for June 25, 2021, has been adjourned due to a lack of quorum. The adjourned meeting will be held at 9:00 a.m. Eastern Time on Friday, July 23, 2021.

Pipeline Therapeutics today announced that Scott Oross has been appointed as General Counsel.

Dexcom announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.